506 related articles for article (PubMed ID: 8395053)
1. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
[TBL] [Abstract][Full Text] [Related]
2. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase.
Vogel Z; Barg J; Levy R; Saya D; Heldman E; Mechoulam R
J Neurochem; 1993 Jul; 61(1):352-5. PubMed ID: 8515284
[TBL] [Abstract][Full Text] [Related]
3. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
4. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
5. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
6. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells.
Mackie K; Devane WA; Hille B
Mol Pharmacol; 1993 Sep; 44(3):498-503. PubMed ID: 8371711
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones.
Felder CC; Veluz JS; Williams HL; Briley EM; Matsuda LA
Mol Pharmacol; 1992 Nov; 42(5):838-45. PubMed ID: 1331766
[TBL] [Abstract][Full Text] [Related]
9. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Devane WA; Hanus L; Breuer A; Pertwee RG; Stevenson LA; Griffin G; Gibson D; Mandelbaum A; Etinger A; Mechoulam R
Science; 1992 Dec; 258(5090):1946-9. PubMed ID: 1470919
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid ligand-receptor signaling in the mouse uterus.
Das SK; Paria BC; Chakraborty I; Dey SK
Proc Natl Acad Sci U S A; 1995 May; 92(10):4332-6. PubMed ID: 7753807
[TBL] [Abstract][Full Text] [Related]
11. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
12. Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor.
Hampson AJ; Hill WA; Zan-Phillips M; Makriyannis A; Leung E; Eglen RM; Bornheim LM
Biochim Biophys Acta; 1995 Nov; 1259(2):173-9. PubMed ID: 7488638
[TBL] [Abstract][Full Text] [Related]
13. Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific.
Perez DM; DeYoung MB; Graham RM
Mol Pharmacol; 1993 Oct; 44(4):784-95. PubMed ID: 8232229
[TBL] [Abstract][Full Text] [Related]
14. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling.
Bayewitch M; Avidor-Reiss T; Levy R; Barg J; Mechoulam R; Vogel Z
FEBS Lett; 1995 Nov; 375(1-2):143-7. PubMed ID: 7498464
[TBL] [Abstract][Full Text] [Related]
15. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses.
Bonhaus DW; Chang LK; Kwan J; Martin GR
J Pharmacol Exp Ther; 1998 Dec; 287(3):884-8. PubMed ID: 9864268
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.
Ross RA; Gibson TM; Brockie HC; Leslie M; Pashmi G; Craib SJ; Di Marzo V; Pertwee RG
Br J Pharmacol; 2001 Feb; 132(3):631-40. PubMed ID: 11159715
[TBL] [Abstract][Full Text] [Related]
17. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells.
Basavarajappa BS; Hungund BL
J Neurochem; 1999 Feb; 72(2):522-8. PubMed ID: 9930723
[TBL] [Abstract][Full Text] [Related]
18. Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors.
Christopoulos A; Wilson K
Brain Res; 2001 Oct; 915(1):70-8. PubMed ID: 11578621
[TBL] [Abstract][Full Text] [Related]
19. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission.
Hampson AJ; Bornheim LM; Scanziani M; Yost CS; Gray AT; Hansen BM; Leonoudakis DJ; Bickler PE
J Neurochem; 1998 Feb; 70(2):671-6. PubMed ID: 9453561
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and behavioral evaluation of alkylated anandamide analogs.
Adams IB; Ryan W; Singer M; Razdan RK; Compton DR; Martin BR
Life Sci; 1995; 56(23-24):2041-8. PubMed ID: 7776830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
